Golgin-300: Key Component of The Golgi Network and Potential Drug Target

Target Name: GOLGA8M

NCBI ID: G653720

GOLGA8M

Other Name(s): Golgin subfamily A member 8M | GOG8M_HUMAN | Golgin A8 family member M | Putative golgin subfamily A member 6-like protein 7 | golgin A8 family member M

Golgin-300: Key Component of The Golgi Network and Potential Drug Target

The Golgi complex is a network of organelles that play a crucial role in the proper functioning of cells. It is a complex system of filaments, button-like structures, and vesicles that are involved in the transport and manipulation of proteins within the cell. Golgi complex is composed of several subfamilies, each of which has its own unique features and functions. One of these subfamilies is the Golgin subfamily A, which is characterized by the presence of the protein known as Golgin-300.

Golgin-300 is a type of protein that is synthesized in the Golgi complex. It is made up of four domains: a N-terminus, a transmembrane region, a tail, and a C-terminus. The N-terminus of Golgin-300 is responsible for its ability to interact with other proteins in the Golgi complex. The transmembrane region is responsible for allowing Golgin-300 to enter and exit the Golgi membrane, while the tail is responsible for its stability and stability. The C-terminus of Golgin -300 is responsible for its ability to interact with the cytoskeleton and other cellular structures.

One of the functions of Golgin-300 is its role in the regulation of the Golgi network. Golgin-300 is involved in the formation and maintenance of the endoplasmic reticulum, which is the structure that transports proteins from the Golgi network to the cell surface. It is also involved in the regulation of the transport of proteins to and from the endoplasmic reticulum, as well as the regulation of the stability of the Golgi network.

Another function of Golgin-300 is its potential as a drug target. The Golgi network is a complex system that is involved in the delivery and manipulation of proteins to the cell surface, making it an attractive target for the development of new pharmaceuticals. -300 protein is a key component of the Golgi network, and its regulation of the network's functions makes it an attractive target for drug development.

Golgin-300 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The Golgi network is involved in the delivery and manipulation of proteins that are involved in the development and progression of these diseases, and Golgin-300's regulation of the network's functions may be a key factor in the development of these diseases.

In conclusion, Golgin-300 is a protein that is synthesized in the Golgi complex and is involved in the regulation of the Golgi network. Its regulation of the network's functions makes it an attractive target for the development of new pharmaceuticals, and its potential as a biomarker for various diseases makes it an important molecule to study. Further research is needed to fully understand the role of Golgin-300 in the Golgi network and its potential as a drug target and biomarker.

Protein Name: Golgin A8 Family Member M

The "GOLGA8M Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GOLGA8M comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets